“Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences” Marelia Barreca, et al. Explor Target Antitumor Ther. 2022; 3(6): 763–794. Published online 2022 Dec 26. doi: 10.37349/etat.2022.00112 PMID: 36654819 Relevant Ancell Research Products anti-human CD269(BCMA) mAb human CD269(BCMA) Recombinant Protein anti-human CD22 mAb anti-human CD79b anti-CD19 mAb

“Prenol, but Not Vitamin C, of Fruit Binds to SARS-CoV-2 Spike S1 to Inhibit Viral Entry: Implications for COVID-19” Ramesh K. Paidi , Kalipada Pahan , et al. (May 2023) Journal of Immunology 210 (12): 1938–1949. https://doi.org/10.4049/jimmunol.2200279 PMID: 37144841

Using a yeast display system, his group developed a BCMA mutant with higher affinity to TNF ligands APRIL and BAFF. This soluble decoy receptor showed anti-tumor effects in vitro and in vivo using mouse MM1.R and INA-6 tumor models. “Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma” Yu Rebecca

Plasma derived neuronal enriched extracellular vesicles(EVs) were evaluated for content of α-synuclein and phosphorylated tau181. Ratio of α-synuclein to phosphorylated tau181 in these samples was signicantly higher for cognitively impaired Parkinson’s patients compared to cognitively normal Parkinson’s patients. Analysis of plasma EVs may be useful for prognosis of Parkinson’s disease. “Extracellular vesicle biomarkers for cognitive

“Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies” doi: 10.1136/jitc-2022-005018. PMID: 36323431 Karin Hägerbrand , Peter Ellmark, et al. J Immunother Cancer 2022 Nov;10(11):e005018 Tetrameric Bispecific antibodies specific to CD40 and either CD326(EpCAM) or CD66e(CEA) were tested on human cells in vitro

This study looked at the effect of glycosylation of anti-platelet antibody on ability of Macrophage mediated phagocytotic clearance in transfusion patients. F(ab’)2 of anti-CD64 mAb was used as a phagocytosis blocking control in vitro. “Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages“ Thijs L, Gesture Vidarsson, et al. Platelets  (2022) https://doi.org/10.1080/09537104.2022.2129604 

Ancell CD166/FITC used as a Mesenchymal marker to characterize Adipose Tissue-Derived Multilineage Progenitor cells (ADMPC) used for Periodontal transplant. The results of this study suggest tha autologous ADMPC transplantation may be a good option for treatment of severe periodontitis. “Periodontal Regeneration by Allogeneic Transplantation of Adipose Tissue Derived Multi-Lineage Progenitor Stem Cells in vivo.“ M

CD133 specific CAR-macrophages created in situ using NanoPorter hydrogel in combination with CD47 checkpoint blocking antibody improves post operative Glioblastoma survival in a humanized mouse model “Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy” Chen Chen, Xinyi Jiang, et al. Science Translational Medicine 14: 656 DOI: 10.1126/scitranslmed.abn1128 CD47

Siglecs and their ligands are expressed by many tumors, and can serve to down-regulate immune response. REVIEW article: “The intriguing roles of Siglec family members in the tumor microenvironment” Kui-Ying Jiang, Ling Wang, et al. (2022) Biomarker Research 10: 22 PMID: 35418152 “Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10” Shan-Shan Yin, Feng-Hou Gao

CF33-hNIS, a modified vaccinia (small pox) virus will be tested by IV or Intratumoral injection, with or without PD-1 inhibitor, pembrolizumab in patients with advanced or metastaic solid tumors. Link to Medical News Today Article Link to Clinical Trial Link to a Background article Ancell human PD-1 related Research Products CD279(PD-1) CD274 (PD-L1) CD273 (PD-L2)